Aurobindo Pharma in Early Talks for $5-5.5 Billion Zentiva Acquisition

💊

CFO confirmed signing a confidentiality agreement for a potential acquisition of Zentiva, valued at $5-5.5 billion. Talks are in early stages, with a possible announcement in two months if successful. The CFO stressed they won’t overpay and aim for single-digit multiples. Zentiva’s European base aligns with Aurobindo’s strategic plans. Despite shares falling 4% on the news, management dismissed debt concerns, citing strong cash flows and $140 million in hand.